Skip to content

Syndax Pharmaceuticals

US · SNDX #2947 by market cap Listed 2016
8.72 -0.41 -4.49%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • Total institutional ownership fell 3.6 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
119.84% -3.62pp
Institutions
303
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund57.39%
Hedge Fund41.43%
Public Company10.19%
VC/PE Fund6.16%
Private Company2.14%
Individual/Insider0.88%
Endowment Fund0.83%
Insurance Company0.78%
Family Office/Trust0.34%
Government Pension Fund0.58%

Top holders as of 2026-09-30

BlackRock 10.30% · 9.27M sh
Kynam Capital Management, LP 8.94% · 8.05M sh
The Goldman Sachs Group, Inc. 6.04% · 5.44M sh
State Street Global Advisors 5.17% · 4.65M sh
Vanguard Capital Management, LLC 4.39% · 3.95M sh
Deerfield Management Company, L.P. 4.20% · 3.78M sh
Franklin Resources 3.87% · 3.49M sh
Eversept Partners, L.P. 3.11% · 2.80M sh
Bank of America Corporation 2.91% · 2.62M sh
Geode Capital Management, LLC 2.89% · 2.58M sh
Hood River Capital Management LLC 2.85% · 2.56M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 25 buys · 23 sells

NameRoleStake
Keith Katkin Independent Director 0.10%
Pierre Legault Independent Director 0.10%
Jennifer Jarrett Independent Director 0.10%
Martin Huber Independent Director 0.08%
Michael Metzger Chief Executive Officer 0.07%
Nicholas Botwood Head of Research & Development and Chief Medical Officer 0.07%
Keith Goldan Officer 0.03%
Aleksandra Rizo Independent Director 0.03%
Dennis Podlesak Independent Chairperson 0.02%
Neil Gallagher Former President and Head of Research & Development --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-08 Aaron Ondrey CFO, Principal Accounting and Financial Officer & Treasurer Other Derivative Acquisition +270,000 $9.55
2026-10-28 Dennis Podlesak Independent Chairperson Derivative Exercise and Sale -8,000 $11.81–14.21
2026-07-07 Michael Metzger Chief Executive Officer Derivative Exercise and Sale -32,375 $6.38–24.24
2026-06-11 Nicholas Botwood Head of Research & Development and Chief Medical Officer Derivative Exercise and Sale -53,750 $13.82–18.14
2026-06-11 Nicholas Botwood Head of Research & Development and Chief Medical Officer Intent to Sell (Form 144) -31,235 $18.14
2026-06-10 Nicholas Botwood Head of Research & Development and Chief Medical Officer Automatic Disposition -11,765 $18.00
2026-05-31 Keith Goldan Officer Open Market Disposition -1,177 $18.99
2026-05-31 Michael Metzger Chief Executive Officer Open Market Disposition -6,847 $18.99
2026-02-08 Keith Goldan Officer Open Market Disposition -3,410 $21.03
2026-02-08 Michael Metzger Chief Executive Officer Open Market Disposition -17,159 $21.03
2026-02-05 Keith Goldan Officer Open Market Disposition -2,082 $20.62
2026-02-05 Michael Metzger Chief Executive Officer Open Market Disposition -7,412 $20.62
2026-02-03 Keith Katkin Independent Director Other Acquisition +24,000 --
2026-02-03 Pierre Legault Independent Director Other Acquisition +24,000 --
2026-02-03 Keith Goldan Officer Other Acquisition +52,250 --
2026-02-03 Keith Goldan Officer Other Derivative Acquisition +118,000 $20.43
2026-02-03 Dennis Podlesak Independent Chairperson Other Acquisition +48,000 --
2026-02-03 Michael Metzger Chief Executive Officer Other Acquisition +217,600 --
2026-02-03 Michael Metzger Chief Executive Officer Other Derivative Acquisition +440,000 $20.43
2026-02-03 Jennifer Jarrett Independent Director Other Acquisition +24,000 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.

Syndax Pharmaceuticals discussion 0 comments

Add a comment